MDxHealth (NASDAQ:MDXH) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH - Free Report) to a hold rating in a research report report published on Saturday morning.

MDxHealth Stock Performance

Shares of NASDAQ:MDXH traded up $0.05 during trading on Friday, reaching $2.16. The stock had a trading volume of 99,734 shares, compared to its average volume of 86,714. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50. The stock has a fifty day simple moving average of $1.71 and a two-hundred day simple moving average of $1.85. The firm has a market capitalization of $102.14 million, a price-to-earnings ratio of -1.42 and a beta of 1.32. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $24.29 million during the quarter, compared to analyst estimates of $22.62 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. As a group, analysts anticipate that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several hedge funds have recently added to or reduced their stakes in MDXH. AWM Investment Company Inc. increased its position in shares of MDxHealth by 10.6% in the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock worth $7,414,000 after purchasing an additional 499,992 shares during the period. Delta Investment Management LLC raised its position in shares of MDxHealth by 459.1% during the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock worth $270,000 after purchasing an additional 156,100 shares during the period. Perkins Capital Management Inc. raised its position in shares of MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock worth $1,678,000 after purchasing an additional 198,000 shares during the period. Castleview Partners LLC bought a new stake in MDxHealth during the first quarter worth $48,000. Finally, FAS Wealth Partners Inc. grew its stake in MDxHealth by 49.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock valued at $58,000 after purchasing an additional 8,100 shares during the period.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.